DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173652

A review on pregabalin for the treatment of painful diabetic peripheral neuropathy

Aryendu Kumar Saini, Anurag Singh, Aditya Gupta, Shubham Singh

Abstract


Pregabalin is an anti-epileptic drug which has been used for the treatment of diabetic peripheral neuropathy. Earlier, it was more prescribed as an adjuvant therapy for treating the partial seizures with or without secondary generalization in adults. It is an antagonist of voltage sensitive calcium ion channel on the presynaptic neuron. Pregabalin has a very good pharmacokinetic profile, possesses linear pharmacokinetics with low inter-variability of subjects. It does not show protein binding and does not interfere with the metabolism of other drugs because pregabalin undergoes very less metabolism. This factor has confirmedly shown that its benefits outweigh the risk. Different clinical trials and case reports have confirmed the fact that is reduces the pain involved in peripheral neuropathy. Though, more drugs have come like tricyclic antidepressant to manage the pain but due to their adverse effects, they are less used. This reappraisal is all about the pregabalin, its role, and where it stands among other drugs for management of pain aassociaed with diabetic peripheral neuropathy.


Keywords


Carbamazepine, Desipramine, Neuropathy, Pregabalin, Seizures

Full Text:

PDF

References


Freeman R, Durso-DeCruz E, Emir B. Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy: Findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31(7):1448-54. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2453685

Javed S, Petropoulos N, Alam U, Malik AR. Treatment of painful diabetic neuropathy. Therapeutic Advances Chronic Disease. 2015;6(1):15-28. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269610

PubMED Health. ncbi.nlm.nih.gov. 2017. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0023139

Lyrica. Drugs.com. 2017. Available at: https://www.drugs.com/lyrica.html

Lyrica. Rxlist.com. 2017. Available at: http://www.rxlist.com/lyrica-drug/patient-images-side-effects.html

Verma V, Singh N, Jaggi AS. Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms. Curr Neuropharmacol. 2014;12(1):44-56. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915349

Carie E. Peripheral Neuropathy. Healthline.com. 2016. Available at: http://www.healthline.com/health/peripheral-neuropathy?isLazyLoad=false

Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. The Journal of Clinical Pharmacology. 2010 Aug 1;50(8):941-50.

Types of Peripheral Neuropathy- Diabetics/ Non- Diabetic. Diabetic.peripheralneuropathycenter.uchicago.edu. 2016. Available at: http://peripheralneuropathycenter.uchicago.edu/learnaboutpn/typesofpn/diabetes/diabetes.shtml

Cohen K, Shinkazh N, Frank J, Israel L, Fellner C. Pharmacological Treatment of Diabetic Peripheral Neuropathy. P and T. 2015;40(6):372,375-88. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450668

Bian F, Li Z, Offord J, Davis M, McCormick J, Taylor C, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: An ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice. Brain Research. 2006;1075(1):68-80. Available at: http://www.sciencedirect.com/science/article/pii/S0006899305017403?via%3Dihub

Ben-Menachem E. Pregabalin Pharmacology and Its Relevance to Clinical Practice. Epilepsia. 2004;45(s6):13-8. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.0013-9580.2004.455003.x/pdf

Pregabalin and Methylcobalamin Capsules. Dmpharma.co.in. 2015. Available at: http://www.dmpharma.co.in/Pregablin.html

Tripathi KD. Essentials of Medical Pharmacology. 7th Ed. New Delhi: Jaypee Medical Publishers; 2013.

Kulkarni C, Devi P, Madhu K, Ganapathy B, Sarma G, John L. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian Journal of Pharmacology. 2012;44(1):51. Available at: http://www.ijp-online.com/article.asp?issn=0253-7613;year=2012;volume=44;issue=1;spage=51;epage=56;aulast=Devi

Pain Medicines for Diabetic Neuropathy - Topic Overview. WebMd.com. 2015. Available at: http://www.webmd.com/diabetes/tc/pain-medicines-for-diabetic-neuropathy-topic-overview

Tanenberg R, Irving G, Risser R, Ahl J, Robinson M, Skljarevski V, et al. Duloxetine, Pregabalin, and Duloxetine Plus Gabapentin for Diabetic Peripheral Neuropathic Pain Management in Patients with Inadequate Pain Response to Gabapentin: An Open-Label, Randomized, Noninferiority Comparison. Mayo Clinic Proceedings. 2011;86(7):615-26. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127557

Filipe A, Almeida S, Pedroso P, Neves R, Marques S, Sicard E, et al. Single-Dose, Randomized, Open-Label, Two-Way, Crossover Bioequivalence Study of Two Formulations of Pregabalin 300mg Hard Capsules in Healthy Volunteers Under Fasting Conditions. Drugs in R&D. 2015;15(2):195-201. Available at: https://link.springer.com/article/10.1007/s40268-015-0094-8

Johannessen S, Johannessen LC. Antiepileptic Drug Interactions - Principles and Clinical Implications. Current Neuropharmacology. 2010;8(3):254-67. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001218

Gabapentin Dosage Guide with Precautions - Drugs.com. Drugs.com. 2017. Available at: https://www.drugs.com/dosage/gabapentin.html

Mapanga R, Essop M. Damaging effects of hyperglycemia on cardiovascular function: spotlight on glucose metabolic pathways. American Journal of Physiology - Heart and Circulatory Physiology. 2015;310(2):H153-73. Available at: http://ajpheart.physiology.org/content/310/2/H153.figures-only